Dataset Information

Proteomic analysis of ascites from LC and GC patients

ABSTRACT: Proteomic analysis by mass spectrometry was performed to characterize proteins in ascites samples from patients with gastric cancer (N = 7) or liver cirrhosis (N = 3).

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Takatsugu Ishimoto

PROVIDER: PXD037200 | JPOST Repository | Sat Oct 07 00:00:00 BST 2023

REPOSITORIES: jPOST

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 20

Publications

Mesothelial cells with mesenchymal features enhance peritoneal dissemination by forming a protumorigenic microenvironment.

Yonemura Atsuko A Semba Takashi T Zhang Jun J Fan Yibo Y Yasuda-Yoshihara Noriko N Wang Huaitao H Uchihara Tomoyuki T Yasuda Tadahito T Nishimura Akiho A Fu Lingfeng L Hu Xichen X Wei Feng F Kitamura Fumimasa F Akiyama Takahiko T Yamashita Kohei K Eto Kojiro K Iwagami Shiro S Iwatsuki Masaaki M Miyamoto Yuji Y Matsusaki Keisuke K Yamasaki Juntaro J Nagano Osamu O Saya Hideyuki H Song Shumei S Tan Patrick P Baba Hideo H Ajani Jaffer A JA Ishimoto Takatsugu T

Cell reports 20240116 1

Malignant ascites accompanied by peritoneal dissemination contain various factors and cell populations as well as cancer cells; however, how the tumor microenvironment is shaped in ascites remains unclear. Single-cell proteomic profiling and a comprehensive proteomic analysis are conducted to comprehensively characterize malignant ascites. Here, we find defects in immune effectors along with immunosuppressive cell accumulation in ascites of patients with gastric cancer (GC) and identify five dis ...[more]

PMID: 38232734

Similar Datasets

Project description:Gene-expression profiles of hepatitis C-related, early-stage liver cirrhosis Background & Aims: Liver cirrhosis affects 1%M-bM-^HM-^R2% of population and is the major risk factor of hepatocellular carcinoma (HCC). Hepatitis C cirrhosis-related HCC is the most rapidly increasing cause of cancer death in the US. Non-invasive methods have been developed to identify patients with asymptomatic, early-stage cirrhosis, increasing the burden of HCC surveillance, but biomarkers are needed to identify patients with cirrhosis who are most in need of surveillance. We investigated whether a liver-derived 186-gene signature previously associated with outcomes of patients with HCC is prognostic for patients newly diagnosed with cirrhosis but without HCC. Methods: We performed gene expression profile analysis of formalin-fixed needle biopsies from the livers of 216 patients with hepatitis C-related early-stage (Child-Pugh class A) cirrhosis who were prospectively followed for a median of 10 years at an Italian center. We evaluated whether the 186-gene signature was associated with death, progression of cirrhosis, and development of HCC. Results: Fifty-five (25%), 101 (47%), and 60 (28%) patients were classified as having poor-, intermediate-, and good-prognosis signatures, respectively. In multivariable Cox regression modeling, the poor-prognosis signature was significantly associated with death (P=.004), progression to advanced cirrhosis (P<.001), and development of HCC (P=.009). The 10-year rates of survival were 63%, 74%, and 85% and the annual incidences of HCC were 5.8%, 2.2%, and 1.5% for patients with poor-, intermediate-, and good-prognosis signatures, respectively. Conclusions: A 186-gene signature used to predict outcomes of patients with HCC is also associated with outcomes of patients with hepatitis C-related early-stage cirrhosis. This signature might be used to identify patients with cirrhosis in most need of surveillance and strategies to prevent their development of HCC. 216 liver biopsy specimens

			Action	DRS
	AY1_01.mgf	Mgf
	AY1_01.raw	Raw
	AY1_02.mgf	Mgf
	AY1_02.raw	Raw
	AY1_03.mgf	Mgf